NASDAQ$RPTX
Repare Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Repare Therapeutics reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Repare Therapeutics announced the dosing of the first patient in its Phase 1b/2 ATTACC trial of RP-3500 and PARP inhibitor combinations, as well as the dosing of the first patient in the RP-6306 Phase 1 clinical trial. The company's cash and cash equivalents, restricted cash, and marketable securities totaled $301.0 million as of June 30, 2021.
- Dosed first patient in Phase 1b/2 ATTACC clinical trial of ATR inhibitor RP-3500 and PARP inhibitor combinations.
- Planned disclosure of initial monotherapy data from the Phase 1/2 TRESR RP-3500 clinical trial early in 4Q21.
- Announced dosing of first patient in RP-6306 Phase 1 clinical trial.
- Progressed towards first druggable target option exercise in Bristol Myers Squibb collaboration.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$279K
Forward guidance
Repare Therapeutics is focused on the clinical development of its pipeline, research and development programs, and its collaboration with Bristol Myers Squibb.
Tailwinds
- Clinical development of RP-3500 and RP-6306.
- Research and development programs focused on genomic instability and DNA damage repair.
- Collaboration with Bristol Myers Squibb to discover and develop novel therapeutics.
- Advancement of a Polθ inhibitor program.
- Continued progress in early-stage, pre-clinical programs.
Headwinds
- Impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position.
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
- Clinical trial site activation or enrollment rates that are lower than expected.
- Changes in expected or existing competition.
- Unexpected litigation or other disputes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro